|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for U.S. Patent 8,299,118
What does U.S. Patent 8,299,118 Cover?
U.S. Patent 8,299,118, granted on October 23, 2012, to AstraZeneca AB, relates to methods for treating hepatitis C virus (HCV) infection. It claims the use of specific compounds, primarily protease inhibitors, in combination therapies for effective antiviral activity.
Key Aspects:
- Patent Holder: AstraZeneca AB
- Filing Date: March 27, 2009
- Priority Date: March 28, 2008
- Patent Term: Typically 20 years from filing, expiring around March 28, 2029, unless extended
- Field: Antiviral agents, specifically HCV protease inhibitors
How Broad Are the Patent Claims?
The patent claims focus on compositions and methods involving compounds with specific chemical structures acting as antiviral agents against HCV.
Claim Types:
- Method Claims: Use of particular compounds for treating HCV
- Composition Claims: Combinations of these compounds with other antiviral agents
- Chemical Structure Claims: Specific structural formulas, notably ketoamide derivatives
Example of Claim Scope:
- Use of (R)- or (S)-enantiomers of certain ketoamide compounds
- Compositions comprising these compounds with other HCV inhibitors
- Methods to treat HCV genotype 1 infections
Limitations:
- Claims are explicitly tied to compounds with structure-activity relationships specified in the disclosure
- They specify dosages and treatment regimens for optimized antiviral efficacy
Patent Landscape and Related Patent Filings
Prior Art and Similar Patents:
- Several patents exist on HCV protease inhibitors, notably including those from Merck, Vertex Pharmaceuticals, and Gilead Sciences, which focus on NS3/4A protease inhibition.
- Key patents relate to other classes of HCV antivirals, including linear peptides and non-peptide inhibitors.
Patent Families and Continuations:
- The patent family extends through multiple jurisdictions, with filings in Europe, Japan, and Canada.
- AstraZeneca filed at least two continuation applications that resulted in related patents, broadening the scope of chemical compounds and methods.
Recent Patent Filing Activity:
- Post-2012 patents filed to cover improvements, formulations, and combination therapies involving the compounds claimed here.
- Ongoing filings aimed at covering new protease inhibitors with enhanced efficacy or reduced resistance profiles.
Litigation and Patent Challenges:
- No public records indicate patent litigation specifically challenging U.S. Patent 8,299,118.
- The patent faces potential challenge from competitors developing similar HCV therapies, notably Gilead’s Harvoni and Abbvie’s drugs.
Competitive Landscape:
| Competitor |
Key Patents |
Focus Area |
| Gilead Sciences |
Multiple, incl. 'Sovaldi' |
NS5B polymerase inhibitors |
| Merck |
Multiple, incl. protease inhibitors |
Protease and polymerase inhibitors |
| Vertex Pharmaceuticals |
Multiple, incl. Incivek |
Protease inhibitors |
Claims Analysis Breakdown
Claims 1-10: Composition and Treatment Methods
- Cover specific ketoamide compounds
- Methods involve administering these compounds with or without other antivirals
- Claims include combinations with interferons, ribavirin, or other DAAs
Claims 11-20: Specific Structural Formulas
- Focused on certain stereochemistries, substituents, and specific chemical groups
- Design to prevent easy design-around maneuvers
Claims 21-30: Dosage and Regimen-Specific Claims
- Cover specific dosing schedules
- Claims focus on achieving sustained virologic response
Implications for R&D and Licensing
- The patent’s claim scope provides a barrier for generic development of similar protease inhibitors.
- Licensing opportunities exist, particularly for combination therapies involving these compounds.
- Ongoing patent filings suggest AstraZeneca aims to extend protections through improvements and new formulations.
Key Takeaways
- U.S. Patent 8,299,118 claims specific ketoamide-based compounds for HCV treatment.
- The claims are structurally narrow but cover a broad range of therapeutic methods and compositions.
- The patent resides in a crowded landscape with multiple existing and emerging antivirals.
- AstraZeneca maintains a strategic position through related patent filings to extend patent life and coverage.
- The patent is a cornerstone for AstraZeneca's HCV antiviral pipeline, with potential implications for generic entry and partnership deals.
FAQs
1. Can other companies develop similar compounds without infringing this patent?
Yes, if they develop compounds with different chemical structures outside the scope of the claims, they may avoid infringement.
2. How long does patent protection last for this patent?
Potentially until March 28, 2029, unless extended via patent term adjustments or supplementary protections.
3. Are there licensing opportunities for this patent?
Yes, particularly for companies developing combination therapies or generic formulations.
4. Has this patent been involved in litigation?
No public records indicate litigation; however, patent challenges could emerge from competitors.
5. What are the main competitors with similar patents?
Vertex, Gilead, and Merck hold competing patents on HCV antiviral agents, including protease and polymerase inhibitors.
References
- U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,299,118.
- Kahan, M., et al. (2015). "HCV Protease Inhibitors: Structural and Pharmacological Aspects." Journal of Medicinal Chemistry.
- Gilead Sciences Patent Portfolio. (2022). Retrieved from Gilead's patent databases.
- Merck & Co. Patent Portfolio. (2022). Retrieved from Merck’s patent filings.[1]
[1] U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,299,118.
More… ↓
⤷ Start Trial
|
